Document is current
Any future updates will be listed below
-
Authors
Jo, Sumin https://orcid.org/0000-0003-1445-9392
Das, Shipra
Williams, Alan
Chretien, Anne-Sophie https://orcid.org/0000-0003-4685-5568
Pagliardini, Thomas
Le Roy, Aude
Fernandez, Jorge Postigo
Le Clerre, Diane
Jahangiri, Billal https://orcid.org/0000-0001-6512-0693
Chion-Sotinel, Isabelle
Rozlan, Sandra
Dessez, Emilie
Gouble, Agnes
Dusséaux, Mathilde
Galetto, Roman
Duclert, Aymeric
Marcenaro, Emanuela https://orcid.org/0000-0003-4103-7566
Devillier, Raynier https://orcid.org/0000-0002-4045-8310
Olive, Daniel https://orcid.org/0000-0003-1299-4113
Duchateau, Philippe https://orcid.org/0000-0002-3491-9168
Poirot, Laurent
Valton, Julien https://orcid.org/0000-0003-0826-5401
-
Funding
Funding for this research was provided by:
Sandra Rozlan is a Cellectis SA employee. Her work has been funding by Cellectis. SA
Emilie Dessez is a Cellectis SA employee. Her work has been funding by Cellectis. SA
- License Information
-
More Information
Article History
Received: 30 November 2020
Accepted: 24 May 2022
First Online: 30 June 2022
Competing interests
: S.D., S.J., D.L., B.J., I.C.S., A.G., M.D., R.G., J.P.F., A.D., P.D., L.P., and J.V. are Cellectis employees and hold patents related to the engineering process of CAR T cells and TALEN<sup>®</sup> technology. TALEN<sup>®</sup> is a Cellectis’ patented technology. D.O. declares competing interests as being the co-founder and shareholder of Imcheck Therapeutics, Alderaan Biotechnology and Emergence Therapeutics and has research funds from Imcheck Therapeutics, Alderaan Biotechnology, Cellectis SA., and Emergence Therapeutics. A.W., B.J., and M.D. are former Cellectis employee. The remaining authors declare no competing interests.
